Restoration of SMN in Schwann cells reverses myelination defects and improves neuromuscular function in spinal muscular atrophy

Spinal muscular atrophy (SMA) is a neuromuscular disease caused by low levels of SMN protein, primarily affecting lower motor neurons. Recent evidence from SMA and related conditions suggests that glial cells can influence disease severity. Here, we investigated the role of glial cells in the peripheral nervous system by creating SMA mice selectively overexpressing SMN in myelinating Schwann cells (Smn−/−;SMN2tg/0;SMN1SC). Restoration of SMN protein levels restricted solely to Schwann cells reversed myelination defects, significantly improved neuromuscular function and ameliorated neuromuscular junction pathology in SMA mice. However, restoration of SMN in Schwann cells had no impact on motor neuron soma loss from the spinal cord or ongoing systemic and peripheral pathology. This study provides evidence for a defined, intrinsic contribution of glial cells to SMA disease pathogenesis and suggests that therapies designed to include Schwann cells in their target tissues are likely to be required in order to rescue myelination defects and associated disease symptoms.

[1]  Rachael A. Powis,et al.  Selective loss of alpha motor neurons with sparing of gamma motor neurons and spinal cord cholinergic neurons in a mouse model of spinal muscular atrophy , 2016, Journal of anatomy.

[2]  F. Muntoni,et al.  Vascular Defects and Spinal Cord Hypoxia in Spinal Muscular Atrophy , 2016, Annals of neurology.

[3]  T. Crawford,et al.  Astrocytes influence the severity of spinal muscular atrophy. , 2015, Human molecular genetics.

[4]  Robert H. Brown,et al.  Emerging mechanisms of molecular pathology in ALS. , 2015, The Journal of clinical investigation.

[5]  B. Wirth,et al.  Moving towards treatments for spinal muscular atrophy: hopes and limits , 2015, Expert opinion on emerging drugs.

[6]  Chris Henderson.  Faculty Opinions recommendation of Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. , 2014 .

[7]  Rachael A. Powis,et al.  Increased levels of UCHL1 are a compensatory response to disrupted ubiquitin homeostasis in spinal muscular atrophy and do not represent a viable therapeutic target , 2014, Neuropathology and applied neurobiology.

[8]  E. Bloch-Gallego.  Mechanisms controlling neuromuscular junction stability , 2014, Cellular and Molecular Life Sciences.

[9]  R. Ribchester,et al.  Loss of Glial Neurofascin155 Delays Developmental Synapse Elimination at the Neuromuscular Junction , 2014, The Journal of Neuroscience.

[10]  D. Lamont,et al.  Label-free quantitative proteomic profiling identifies disruption of ubiquitin homeostasis as a key driver of Schwann cell defects in spinal muscular atrophy. , 2014, Journal of proteome research.

[11]  T. Gillingwater,et al.  SMN-dependent intrinsic defects in Schwann cells in mouse models of spinal muscular atrophy. , 2014, Human molecular genetics.

[12]  C. Lorson,et al.  Spinal muscular atrophy: a motor neuron disorder or a multi‐organ disease? , 2014, Journal of anatomy.

[13]  X. Paez-Colasante,et al.  Improvement of Neuromuscular Synaptic Phenotypes without Enhanced Survival and Motor Function in Severe Spinal Muscular Atrophy Mice Selectively Rescued in Motor Neurons , 2013, PloS one.

[14]  C. Stucky,et al.  Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production , 2013, Glia.

[15]  R. Kothary,et al.  Defects in neuromuscular junction remodelling in the Smn 2B/− mouse model of spinal muscular atrophy , 2013, Neurobiology of Disease.

[16]  B. Wirth,et al.  Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585 , 2012, European Journal of Human Genetics.

[17]  U. Monani,et al.  Limited Phenotypic Effects of Selectively Augmenting the SMN Protein in the Neurons of a Mouse Model of Severe Spinal Muscular Atrophy , 2012, PloS one.

[18]  M. Bowerman,et al.  Glucose metabolism and pancreatic defects in spinal muscular atrophy , 2012, Annals of neurology.

[19]  M. Rich,et al.  Survival Motor Neuron Protein in Motor Neurons Determines Synaptic Integrity in Spinal Muscular Atrophy , 2012, The Journal of Neuroscience.

[20]  T. Gillingwater,et al.  Density, calibre and ramification of muscle capillaries are altered in a mouse model of severe spinal muscular atrophy , 2012, Neuromuscular Disorders.

[21]  C. Heckman,et al.  Motor Neuron Rescue in Spinal Muscular Atrophy Mice Demonstrates That Sensory-Motor Defects Are a Consequence, Not a Cause, of Motor Neuron Dysfunction , 2012, The Journal of Neuroscience.

[22]  M. Bowerman,et al.  A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology , 2012, Neuromuscular Disorders.

[23]  K. Nave,et al.  Arrest of Myelination and Reduced Axon Growth When Schwann Cells Lack mTOR , 2012, The Journal of Neuroscience.

[24]  B. Wirth,et al.  Reversible molecular pathology of skeletal muscle in spinal muscular atrophy. , 2011, Human molecular genetics.

[25]  N. Nagan,et al.  Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens , 2011, European Journal of Human Genetics.

[26]  D. Schümperli,et al.  Ultrastructural changes in diaphragm neuromuscular junctions in a severe mouse model for Spinal Muscular Atrophy and their prevention by bifunctional U7 snRNA correcting SMN2 splicing , 2010, Neuromuscular Disorders.

[27]  K. Zerres,et al.  Digital necroses and vascular thrombosis in severe spinal muscular atrophy , 2010, Muscle & nerve.

[28]  B. Wirth,et al.  SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. , 2010, Human molecular genetics.

[29]  K. Talbot,et al.  Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy. , 2010, Human molecular genetics.

[30]  C. Beattie,et al.  Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? , 2009, Nature Reviews Neuroscience.

[31]  K. Swoboda,et al.  Vascular perfusion abnormalities in infants with spinal muscular atrophy. , 2009, The Journal of pediatrics.

[32]  Kayoko Saito,et al.  An autopsy case of spinal muscular atrophy type III (Kugelberg‐Welander disease) , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.

[33]  L. Landmesser,et al.  Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. , 2008, Human molecular genetics.

[34]  B. Wirth,et al.  Congenital heart disease is a feature of severe infantile spinal muscular atrophy , 2008, Journal of Medical Genetics.

[35]  K. Talbot,et al.  Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. , 2008, Human molecular genetics.

[36]  K. Fischbeck,et al.  Transgenic Expression of Human Connexin32 in Myelinating Schwann Cells Prevents Demyelination in Connexin32-Null Mice , 2005, The Journal of Neuroscience.

[37]  J. Melki,et al.  Deletion of murine Smn exon 7 directed to liver leads to severe defect of liver development associated with iron overload. , 2004, The American journal of pathology.

[38]  A. Arnold,et al.  Reduced expression of nicotinic AChRs in myotubes from spinal muscular atrophy I patients , 2004, Laboratory Investigation.

[39]  M. A. García-Cabezas,et al.  Neonatal spinal muscular atrophy with multiple contractures, bone fractures, respiratory insufficiency and 5q13 deletion , 2004, Acta Neuropathologica.

[40]  T. Komori,et al.  Neuropathological analysis in spinal muscular atrophy type II , 2003, Acta Neuropathologica.

[41]  Fricker,et al.  Mouse model of spinal muscular atrophy. , 2000, Drug discovery today.

[42]  D. Sherman,et al.  A Tripartite Nuclear Localization Signal in the PDZ-domain Protein L-periaxin* , 2000, The Journal of Biological Chemistry.

[43]  J. McPherson,et al.  A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. , 1999, Human molecular genetics.

[44]  C. Lorson,et al.  A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Melki,et al.  Spinal muscular atrophy. , 1997, Current opinion in neurology.

[46]  J. Warter,et al.  Constitutive muscular abnormalities in culture in spinal muscular atrophy , 1995, The Lancet.

[47]  J. Weissenbach,et al.  Identification and characterization of a spinal muscular atrophy-determining gene , 1995, Cell.

[48]  B. Wirth,et al.  Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy , 2014 .

[49]  G. Hamilton,et al.  Spinal muscular atrophy: going beyond the motor neuron. , 2013, Trends in molecular medicine.